CASTLE BIOSCIENCES INC (CSTL): Price and Financial Metrics


CASTLE BIOSCIENCES INC (CSTL): $21.27

0.20 (+0.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CSTL POWR Grades

  • CSTL scores best on the Sentiment dimension, with a Sentiment rank ahead of 81.67% of US stocks.
  • The strongest trend for CSTL is in Growth, which has been heading up over the past 179 days.
  • CSTL's current lowest rank is in the Momentum metric (where it is better than 1.17% of US stocks).

CSTL Stock Summary

  • The ratio of debt to operating expenses for CASTLE BIOSCIENCES INC is higher than it is for about just 13.25% of US stocks.
  • CSTL's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 8.96% of US stocks.
  • Over the past twelve months, CSTL has reported earnings growth of 116.91%, putting it ahead of 87% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CASTLE BIOSCIENCES INC are ONTF, ROOT, LMND, VHC, and MXCT.
  • Visit CSTL's SEC page to see the company's official filings. To visit the company's web site, go to castlebiosciences.com.

CSTL Valuation Summary

  • In comparison to the median Healthcare stock, CSTL's price/sales ratio is 27.84% higher, now standing at 6.2.
  • CSTL's EV/EBIT ratio has moved up 78.4 over the prior 40 months.

Below are key valuation metrics over time for CSTL.

Stock Date P/S P/B P/E EV/EBIT
CSTL 2022-11-01 6.2 1.6 -15.3 -7.5
CSTL 2022-10-31 6.1 1.6 -15.1 -7.4
CSTL 2022-10-28 5.6 1.5 -13.8 -6.4
CSTL 2022-10-27 5.2 1.4 -13.0 -5.7
CSTL 2022-10-26 5.3 1.4 -13.1 -5.8
CSTL 2022-10-25 5.2 1.4 -12.9 -5.6

CSTL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CSTL has a Quality Grade of D, ranking ahead of 17.49% of graded US stocks.
  • CSTL's asset turnover comes in at 0.205 -- ranking 69th of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows CSTL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.205 0.848 -1.507
2021-03-31 0.211 0.848 -0.890
2020-12-31 0.258 0.845 -0.387
2020-09-30 0.386 0.857 -0.011
2020-06-30 0.451 0.868 0.367
2020-03-31 0.627 0.866 0.356

CSTL Price Target

For more insight on analysts targets of CSTL, see our CSTL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $88.50 Average Broker Recommendation 1.17 (Strong Buy)

CSTL Stock Price Chart Interactive Chart >

Price chart for CSTL

CSTL Price/Volume Stats

Current price $21.27 52-week high $48.40
Prev. close $21.07 52-week low $15.58
Day low $20.08 Volume 40,900
Day high $21.32 Avg. volume 272,451
50-day MA $23.58 Dividend yield N/A
200-day MA $28.15 Market Cap 560.51M

CASTLE BIOSCIENCES INC (CSTL) Company Bio


Castle Biosciences, Inc. provides healthcare imaging services. The Company offers diagnostic and prognostic testing solutions for cancers, as well as research and development activities. Castle Biosciences serves customers in the United States.


CSTL Latest News Stream


Event/Time News Detail
Loading, please wait...

CSTL Latest Social Stream


Loading social stream, please wait...

View Full CSTL Social Stream

Latest CSTL News From Around the Web

Below are the latest news stories about CASTLE BIOSCIENCES INC that investors may wish to consider to help them evaluate CSTL as an investment opportunity.

Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory

FRIENDSWOOD, Texas, November 21, 2022--Castle announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory in Pittsburgh.

Yahoo | November 21, 2022

Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results

FRIENDSWOOD, Texas, November 17, 2022--Castle announced the publication of a study in collaboration with the MRF to assess patient experiences with prognostic testing in uveal melanoma.

Yahoo | November 17, 2022

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

FRIENDSWOOD, Texas, November 15, 2022--Castle announced new data showing the independent and significant risk-stratification of DecisionDx-SCC in cSCC tumors with ambiguous histology.

Yahoo | November 15, 2022

Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year

FRIENDSWOOD, Texas, November 14, 2022--Castle Biosciences has been named a Houston Chronicle Top Workplace for the second year in a row.

Yahoo | November 14, 2022

Increasing losses over year doesn't faze Castle Biosciences (NASDAQ:CSTL) investors as stock jumps 11% this past week

Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders should be happy to see the share price up 11% in the last week...

Yahoo | November 3, 2022

Read More 'CSTL' Stories Here

CSTL Price Returns

1-mo -3.27%
3-mo -31.25%
6-mo N/A
1-year -50.67%
3-year -21.37%
5-year N/A
YTD -50.38%
2021 -36.16%
2020 95.37%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.655 seconds.